Minocycline in the treatment OCD

Minocycline in the treatment of mild to moderate OCD: a randomized and double blinid trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201501031556N70

Enrollment

Registered

2015-01-04

Start date

2015-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Fluvoxamine 100 mg/day + placebo for 10 weeks as control group. Intervention 2: Fluvoxamine 100 mg/day+ Minocycline 200 mg/day for 10 weeks as intervention group.

Placebo

Treatment - Drugs

Fluvoxamine 100 mg/day + placebo for 10 weeks as control group

Fluvoxamine 100 mg/day+ Minocycline 200 mg/day for 10 weeks as intervention group

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1-Age between 18-60 years old; 2-Diagnosis of OCD based on DSM 5; 3- Minimum Score of 21 on YALE-BROWN Obsessive-Compulsive Scale. Exclusion Criteria:1- Substance dependence; 2- IQ <70; 3-Any other mental disorder; 4-Any serious cardiac, renal or hepatic disease; 5- receiving psychotropic medications during the last 6 weeks; 6- pregnancy or breast feeding; 7-suicidal thoughts.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of symptoms of OCD. Timepoint: Baseline and weeks 2-4-8-10 after beginig of treatment. Method of measurement: Y_BOCS.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactProf. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026